EGFR S768I
|
NSCLC
|
EGFR S768I
|
NSCLC
|
dacomitinib Sensitive: C2 – Inclusion Criteria
Front Pharmacol - 3 weeks (New C2)
|
dacomitinib Sensitive: C2 – Inclusion Criteria
Front Pharmacol - 3 weeks - (New C3)
|
EGFR S768I
|
NSCLC
|
EGFR S768I
|
NSCLC
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
EGFR S768I
|
NSCLC
|
EGFR S768I
|
NSCLC
|
osimertinib Sensitive: C2 – Inclusion Criteria
|
osimertinib Sensitive: C2 – Inclusion Criteria
|
EGFR S768I
|
NSCLC
|
EGFR S768I
|
NSCLC
|
gefitinib Resistant: C3 – Early Trials
|
gefitinib Resistant: C3 – Early Trials
|
EGFR S768I
|
NSCLC
|
EGFR S768I
|
NSCLC
|
erlotinib Sensitive: C3 – Early Trials
|
erlotinib Sensitive: C3 – Early Trials
|
EGFR S768I
|
LUAD
|
EGFR S768I
|
LUAD
|
afatinib Resistant: C3 – Early Trials
|
afatinib Resistant: C3 – Early Trials
|
EGFR S768I
|
NSCLC
|
EGFR S768I
|
NSCLC
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
EGFR S768I
|
LUAD
|
EGFR S768I
|
LUAD
|
erlotinib Sensitive: C4 – Case Studies
|
erlotinib Sensitive: C4 – Case Studies
|